Savvy Advisors Inc. Makes New $222,000 Investment in Cencora, Inc. (NYSE:COR)

Savvy Advisors Inc. bought a new stake in shares of Cencora, Inc. (NYSE:COR) in the third quarter, Holdings Channel reports. The firm bought 985 shares of the company’s stock, valued at approximately $222,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Price T Rowe Associates Inc. MD acquired a new stake in Cencora during the first quarter valued at $2,183,619,000. JPMorgan Chase & Co. purchased a new stake in shares of Cencora during the 1st quarter worth about $1,199,695,000. Boston Partners acquired a new stake in shares of Cencora during the 1st quarter valued at about $1,001,269,000. Capital Research Global Investors bought a new stake in shares of Cencora in the 1st quarter valued at approximately $650,424,000. Finally, Bessemer Group Inc. acquired a new position in Cencora in the first quarter worth approximately $556,245,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Price Performance

Shares of NYSE:COR opened at $249.95 on Thursday. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The business has a 50 day moving average price of $232.38 and a 200 day moving average price of $231.00. The company has a market cap of $49.25 billion, a price-to-earnings ratio of 33.28, a PEG ratio of 1.66 and a beta of 0.44. Cencora, Inc. has a twelve month low of $191.11 and a twelve month high of $251.56.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be paid a $0.55 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.88%. Cencora’s dividend payout ratio (DPR) is presently 27.16%.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on COR. Wells Fargo & Company lifted their target price on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. Robert W. Baird lifted their price objective on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. JPMorgan Chase & Co. boosted their price target on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Finally, UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $271.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.